Galectin Therapeutics to Present at 7th Annual LD Micro

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference

NORCROSS, Ga., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq: GALT ), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James C. Czirr, executive chairman of the Company's board of directors, will present at the LD Micro "Main Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014 at 11:30 a.m. PST at the Luxe Sunset Bel Air Hotel in Los Angeles, Calif.

The presentation will include a Company overview and financial briefing, a summary of key accomplishments from 2014 including a review of the Company's Phase 1 clinical trial of GR-MD-02 in fatty liver disease with advanced fibrosis, and a discussion of upcoming milestones in 2015.

Czirr noted, "This year has been a particularly exciting time for Galectin Therapeutics, as we complete the Phase 1 clinical trial of our propriety galectin inhibitor in fatty liver disease, a condition affecting between nine and 15 million Americans. Liver transplantation is currently the only therapeutic approach to fatty liver disease or other forms of liver fibrosis as there are no drug therapies on the market. What we have seen in our Phase 1 trial is that GR-MD-02 is safe and well tolerated at multiple doses. We also found a reduction for serum biomarker alpha-2 macroglobulin, a key indicator in liver fibrosis. This data was presented by Stephen A. Harrison, M.D., Chief of Hepatology at Brooke Army Medical Center, at the American Association for the Study of Liver Diseases' The Liver Meeting, which represents the largest and most prestigious liver meeting in the world, attended by thousands of physicians, scientists and researchers from around the globe. We believe that galectin inhibition plays a role in liver fibrosis, and our upcoming Phase 2 clinical trial will increase our scientific understanding of this galectin effect."

Czirr will be available for one-on-one meetings on the day of the presentation. His presentation will be available as a live and archived webcast at the following address: http://wsw.com/webcast/ldmicro7/galt .

About LD Micro

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm hosts the LD Micro "Main Event" Micro-Cap Growth Conference for investors in December of each year. This year's conference will feature presentations by over 240 publicly traded companies and is expected to attract more than 1,000 attendees. For additional information, please visit the LD Micro conference website at http://www.ldmicro.com .

About Galectin Therapeutics

Galectin Therapeutics (Nasdaq: GALT ) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com .

Forward-Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. These statements include those regarding our plans, expectations and goals regarding clinical trials, including our expectation that a final clinical data report from the third cohort should be available in January 2015, plans regarding design and composition and timing of a Phase 2 clinical trial, and plans regarding future funding alternatives and the sufficiency of cash on hand to fund future operations and planned research and development through mid-2016. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding any clinical trial or any future trials are subject to factors beyond our control and there is no guarantee that we will avoid delays in the development of our drug products or receive FDA approval for any of our drugs in development. Any current clinical trials and any future trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of a trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would impact our estimates regarding timing, and we may not be able to achieve the desired results. Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse impact on our ability to achieve revenues from any proposed indications. Plans regarding development, approval and marketing of any of our drugs, including GR-MD-02, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC.  You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Galectin Therapeutics Inc. Peter G. Traber, MD, 678-620-3186 President, CEO, & CMO

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 105

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Sophia Space Tests the Software Layer for Orbit Ahead

Updated Category News Views 37

Orbit got a little less theoretical when Sophia Space put its operating system across multiple Kepler Communications satellites. That is not a finished orbital data center, despite the inevitable big-language parade around this sort of announcement. It is a software deployment, a real one, aboard Kepler's Tranche 1 optical data relay constellation. In an industry stuffed...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 62

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
iFLYTEK’s AINOTE Discounts Put E-Ink Utility on Trial

Updated Category News Views 6

A slim E-Ink notebook is getting shoved into the Black Friday brawl, and iFLYTEK is betting that less screen glare and more follow-through can still command a serious price. The company has put discounts of up to 25% on its AINOTE lineup, a sensible move in a gadget season where buyers have no shortage of tablets, voice apps, and half-used productivity subscriptions...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 61

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 167

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 77

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
California Budget Warning Puts Reserves Back in Focus

Updated Category News Views 28

California’s rainy-day umbrella is getting another hard look, and it should. State Controller Malia M. Cohen is pointing to the Legislative Analyst’s Office fiscal outlook as a reminder that budget discipline and stronger reserves are not ornamental good-government phrases. They are the difference between absorbing a revenue wobble and reaching for ugly fixes after...

Continue Reading
OCEG Faces China's Demographic Test After 40 Years

Updated Category News Views 83

A school group that once opened 35 kindergartens in a year is admitting the old playbook has run its course. That is the real message behind Oriental Cambridge Education Group's 40th-anniversary talk, not the balloons and ceremonial language. OCEG operates more than 170 institutions across 39 Chinese cities, and its chairman, Yu Yue, says the next chapter will be judged...

Continue Reading

Top 5 Most Recently Viewed Articles

Radius Insights Launches New Technology Research Practice

Updated Category News Views 131

Radius Insights Launches Radius Tech A focused expansion of Radius' technology expertise aims to help tech brands make smarter, faster growth decisions. Radius Insights recently unveiled the launch of Radius Tech, a dedicated technology division within Radius designed to deliver precise market research and customer insights specifically tailored for technology companies....

Continue Reading
Urgent Reminder for WM Technology Shareholders on Lead Plaintiff Deadline

Updated Category News Views 176

Important Information for WM Technology Shareholders The Gross Law Firm is reaching out to shareholders of WM Technology, Inc. (NASDAQ: MAPS). This notice serves as a crucial reminder regarding the upcoming deadline for appointing a lead plaintiff in the class action lawsuit involving the company. Who Should Contact the Gross Law Firm? If you have purchased shares of MAPS...

Continue Reading
Gaxos.ai to Skyrocket Connections at Unite 2024 Conference

Updated Category News Views 71

Gaxos.ai's Involvement at Unite 2024 Conference Gaxos.ai Inc. is preparing for a major presence at the Unite 2024 Conference, a vibrant event dedicated to showcasing the latest innovations in gaming and technology. This conference is well-known for bringing together game developers, artists, and tech enthusiasts. Running from September 18 to September 20, Gaxos is eager...

Continue Reading
XNRGY Climate Systems Completes Strategic Growth Financing

Updated Category News Views 365

XNRGY Climate Systems Strengthens Financial Foundation XNRGY Climate Systems, recognized as a key player in sustainable technologies, recently revealed that it has effectively finalized its financing round. This includes a significant investment partnership with Capital Bridge Group and Prologis Ventures. With this move, XNRGY aims to push forward its mission of advancing...

Continue Reading
BioLife Solutions Sells SAVSU to Enhance Logistics Strategy

Updated Category News Views 211

BioLife Solutions Completes Strategic Sale of SAVSU BioLife Solutions, Inc. (Nasdaq: BLFS), a prominent provider of cell processing tools for the cell and gene therapy market, has recently announced a significant event in its operational strategy. The company has sold its wholly owned cold chain logistics subsidiary, SAVSU Cleo Technologies, LLC., previously known as...

Continue Reading